top of page
  • The San Juan Daily Star

Long-lasting injectable PrEP medication reaches Puerto Rico

By The Star Staff

Recently, Prepven Health Clinic began providing their long-acting injectable HIV preventive medication (PrEP) to the first patient in Hato Rey, Puerto Rico. “Apretude” is the first HIV treatment that does not require the patient to take daily doses for the same purpose. This medication, when administered every two months, reduces the risk of contracting HIV sexually.

PrEP is a medical therapy used as HIV pre-exposure prevention, according to Prepven Health Clinic’s website. People at high risk of contracting HIV take these medications and, when taken as directed and consistently, they are highly effective in preventing infection.

There are currently three approved therapies for PrEP or HIV prevention use: Truvada, Descovy, and Apretude (first injectable). When taken daily, without intermittency, the drug can be up to 99% effective in reducing the acquisition of the virus.

Even though there’s still no vaccine against HIV, PrEP treatments can prevent acquiring the illness.

“According to the FDA Center for Drug Evaluation and Research’s Division of Antivirals, the approval of Apretude will help improve access to treatment for high-risk patients. For many, these drugs have proven inaccessible over the years. We are here to change that reality,” said Dr. Ronald Collazo Pagán.

Prepven is a non-profit organization conceptualized to mobilize certain clinical aspects of HIV, STD, hepatitis prevention, and their treatments into a new medical/technological era. Our goal is to reach more patients wherever they are to facilitate access to the treatments we offer so they can have a better quality of life.

For more information about the drug, the clinic, and other treatments, visit

29 views0 comments
bottom of page